FDA approves lifileucel, the first tumor-derived T-cell therapy, for advanced melanoma
Evidence stage: Later-Stage HumanRegulatory status: FDA Approved
In the single-arm, open-label C-144-01 trial, a one-time infusion of a patient's own expanded tumor-infiltrating lymphocytes (lifileucel) produced an objective response in 31.5% of patients with advanced melanoma who had…
Primary source cited
Last reviewed